Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Randomized, Open-Label, Phase 3 Study to Assess the Efficacy and Safety of KRN23 Versus Oral Phosphate and Active Vitamin D Treatment in Pediatric Patients with X-linked Hypophosphatemia (XLH)

Next Previous
Trial Profile

A Randomized, Open-Label, Phase 3 Study to Assess the Efficacy and Safety of KRN23 Versus Oral Phosphate and Active Vitamin D Treatment in Pediatric Patients with X-linked Hypophosphatemia (XLH)

Status: Completed
Phase of Trial: Phase III

Latest Information Update: 24 Jul 2023

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Burosumab (Primary) ; Alfacalcidol; Calcitriol; Potassium phosphate; Vitamin D
  • Indications X-linked dominant hypophosphataemic rickets
  • Focus Registrational; Therapeutic Use
  • Acronyms PIXLES
  • Sponsors Kyowa Kirin; Ultragenyx Pharmaceutical

    • Most Recent Events

    • 12 Apr 2023 Results of sub group analysis assessing analysis to determine whether skeletal responses differed when switching to burosumab versus continuing higher or lower doses of conventional therapy published in the Journal of Clinical Endocrinology and Metabolism
    • 09 May 2022 Results of a post hoc analysis assessed the impact of age on burosumab efficacy and safety in X-linked hypophosphatemia published in the Journal of Clinical Endocrinology and Metabolism
    • 01 Jul 2021 Results assessing the reliability, validity, and sensitivity to change of the RGI-C were evaluated using data from two studies (NCT02163577, NCT02915705) in pediatric XLH published in the Bone
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Legal
Back to top